Silence Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
A proprietary siRNA platform supports three clinical programs, including phase II SLN124 for polycythemia vera and phase III-ready SLN360 for Lp(a), both showing robust efficacy and differentiated dosing. Key milestones include phase II data in Q3 2025 and strong financial runway into 2028.
-
The conference highlighted robust progress in siRNA-based therapies, with strong phase 1 and 2 data for PV and Lp(a) programs, strategic partnerships, and a solid cash runway. AI integration and regulatory flexibility are shaping R&D, while focus remains on PV trial completion and Lp(a) partnering.
-
The conference highlighted a robust siRNA pipeline with phase III-ready and first-in-class assets targeting major unmet needs in cardiovascular and hematological diseases. Strong clinical data, global regulatory support, and a solid financial runway position the company for growth.
Fiscal Year 2024
-
Strong 2024 results driven by collaboration revenue and pipeline progress, with zerlasiran Phase III on hold pending partnership and divesiran advancing in PV. Cash runway now extends into 2027, and strategic focus shifts to rare disease siRNA programs.
-
The company highlighted strong progress in its siRNA pipeline, with zerlasiran showing over 90% Lp(a) knockdown and infrequent dosing, and divesiran demonstrating robust efficacy in PV. Phase 3 for zerlasiran will target a broad cardiovascular population, while partnerships and a solid cash position support ongoing development.
-
Key siRNA programs demonstrated strong efficacy and durability in Lp(a) and PV, with phase 3 Lp(a) trials set for mid-next year. Physician demand is high for new therapies, and partnerships with AstraZeneca and Hansoh support a robust pipeline.
-
A proprietary siRNA platform is advancing multiple clinical programs, including zerlasiran for Lp(a) and divesiran for polycythemia vera, both showing robust efficacy in early trials. With strong partnerships, a solid cash runway, and a broad pipeline, the company is poised for significant growth.
-
Precision siRNA medicines are advancing through late-stage clinical trials, targeting major unmet needs in cardiovascular and hematological diseases. Lead programs show strong efficacy and safety, with significant market potential and robust partnerships driving growth.
-
The conference highlighted strong clinical progress for siRNA programs in cardiovascular and rare blood diseases, with lead assets showing robust efficacy, safety, and infrequent dosing. Upcoming data and regulatory milestones are expected to drive further development and market differentiation.
-
The platform's siRNA technology targets major unmet needs in cardiovascular and orphan diseases, with lead programs showing robust efficacy and durability. Zerlasiran is advancing to Phase 3 for Lp(a) reduction, while the PV program aims for Phase 2 by year-end, both supported by strong partnerships and a solid cash position.
-
Divesiran in Phase 1 for PV showed strong efficacy, with all well-controlled patients avoiding phlebotomy and only 2 phlebotomies in less controlled patients. The drug was well tolerated, improved iron status, and demonstrated robust target engagement.